Clinical trajectories in the ultra-high risk for psychosis population

Andrea Polari, Suzie Lavoie, Hok-Pan Yuen, Paul Amminger, Gregor Berger, Eric Chen, Lieuwe deHaan, Jessica Hartmann, Connie Markulev, Fritha Melville, Dorien Nieman, Merete Nordentoft, Anita Riecher-Rössler, Stefan Smesny, John Stratford, Swapna Verma, Alison Yung, Patrick McGorry, Barnaby Nelson

Research output: Contribution to journalArticleAcademicpeer-review

49 Citations (Scopus)

Abstract

Background: Traditionally, research in the ultra-high risk (UHR) for psychosis population has focused on the treatment of existing symptomatology and prevention of transition to psychosis. Recently, there has been an increase in focus on outcomes in individuals who do not transition to psychosis. However, there is a lack of standardised definitions of remission, recovery, recurrence and relapse in UHR, resulting in the inability to generalise and replicate outcomes. Method: The aims of the current study were to develop definitions for remission, recovery, recurrence and relapse, and apply them to a UHR cohort allowing the identification of longitudinal clinical trajectories. Further stratification in broader categories of favourable and unfavourable outcomes was applied. The predictive value of various baseline factors on specific clinical trajectories was also assessed. Results: 17 different trajectories were identified in a cohort of 202 individuals within a 12-month period and classified according to the suggested definitions for recovery (35.7%), remission (7.5%), any recurrence (20%), no remission (17.3%), relapse (4.0%) and transition to psychosis (15.8%). Favourable and unfavourable trajectories represented 43.2% and 57.1% respectively. Long duration of untreated symptoms and high depression scores were associated with unfavourable outcomes. Discussion: It is possible to apply clear definitions of remission, recovery, recurrence, relapse and transition to psychosis to a UHR cohort to evaluate longitudinal clinical trajectories. Acceptance and use of these definitions will help to facilitate comparisons between trials and to improve clinical clarity across the range of available therapeutic options in UHR individuals.
Original languageEnglish
Pages (from-to)550-556
JournalSchizophrenia Research
Volume197
DOIs
Publication statusPublished - 2018

Cite this